Literature DB >> 33322579

The Role of Epigenomics in Osteoporosis and Osteoporotic Vertebral Fracture.

Kyoung-Tae Kim1,2, Young-Seok Lee1,3, Inbo Han4.   

Abstract

Osteoporosis is a complex multifactorial condition of the musculoskeletal system. Osteoporosis and osteoporotic vertebral fracture (OVF) are associated with high medical costs and can lead to poor quality of life. Genetic factors are important in determining bone mass and structure, as well as any predisposition for bone degradation and OVF. However, genetic factors are not enough to explain osteoporosis development and OVF occurrence. Epigenetics describes a mechanism for controlling gene expression and cellular processes without altering DNA sequences. The main mechanisms in epigenetics are DNA methylation, histone modifications, and non-coding RNAs (ncRNAs). Recently, alterations in epigenetic mechanisms and their activity have been associated with osteoporosis and OVF. Here, we review emerging evidence that epigenetics contributes to the machinery that can alter DNA structure, gene expression, and cellular differentiation during physiological and pathological bone remodeling. A progressive understanding of normal bone metabolism and the role of epigenetic mechanisms in multifactorial osteopathy can help us better understand the etiology of the disease and convert this information into clinical practice. A deep understanding of these mechanisms will help in properly coordinating future individual treatments of osteoporosis and OVF.

Entities:  

Keywords:  DNA methylation; epigenetics; genetic factor; histone modification; non-coding RNA; osteoporosis; osteoporotic vertebral fracture

Year:  2020        PMID: 33322579      PMCID: PMC7763330          DOI: 10.3390/ijms21249455

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  120 in total

Review 1.  Fracture healing: the diamond concept.

Authors:  Peter V Giannoudis; Thomas A Einhorn; David Marsh
Journal:  Injury       Date:  2007-09       Impact factor: 2.586

2.  EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification.

Authors:  Sarah Hemming; Dimitrios Cakouros; Sandra Isenmann; Lachlan Cooper; Danijela Menicanin; Andrew Zannettino; Stan Gronthos
Journal:  Stem Cells       Date:  2014-03       Impact factor: 6.277

3.  Histone deacetylase inhibitors promote osteoblast maturation.

Authors:  Tania M Schroeder; Jennifer J Westendorf
Journal:  J Bone Miner Res       Date:  2005-08-08       Impact factor: 6.741

4.  GADD45A protein plays an essential role in active DNA demethylation during terminal osteogenic differentiation of adipose-derived mesenchymal stem cells.

Authors:  Rui-peng Zhang; Jian-zhong Shao; Li-xin Xiang
Journal:  J Biol Chem       Date:  2011-09-14       Impact factor: 5.157

5.  A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population.

Authors:  Karen Staehling-Hampton; Sean Proll; Bryan W Paeper; Lei Zhao; Patrick Charmley; Analisa Brown; Jessica C Gardner; David Galas; Randall C Schatzman; Peter Beighton; Socrates Papapoulos; Herman Hamersma; Mary E Brunkow
Journal:  Am J Med Genet       Date:  2002-06-15

6.  LncRNA expression profiles and the negative regulation of lncRNA-NOMMUT037835.2 in osteoclastogenesis.

Authors:  Yongyun Chang; Degang Yu; Wenxiang Chu; Zhiqing Liu; Huiwu Li; Zanjing Zhai
Journal:  Bone       Date:  2019-10-05       Impact factor: 4.398

7.  EZH1 and EZH2 promote skeletal growth by repressing inhibitors of chondrocyte proliferation and hypertrophy.

Authors:  Julian C Lui; Presley Garrison; Quang Nguyen; Michal Ad; Chithra Keembiyehetty; Weiping Chen; Youn Hee Jee; Ellie Landman; Ola Nilsson; Kevin M Barnes; Jeffrey Baron
Journal:  Nat Commun       Date:  2016-11-29       Impact factor: 14.919

8.  Bone-Targeting AAV-Mediated Gene Silencing in Osteoclasts for Osteoporosis Therapy.

Authors:  Yeon-Suk Yang; Jun Xie; Sachin Chaugule; Dan Wang; Jung-Min Kim; JiHea Kim; Phillip W L Tai; Seok-Kyo Seo; Ellen Gravallese; Guangping Gao; Jae-Hyuck Shim
Journal:  Mol Ther Methods Clin Dev       Date:  2020-04-18       Impact factor: 6.698

Review 9.  Mesenchymal Stem Cells: Cell Fate Decision to Osteoblast or Adipocyte and Application in Osteoporosis Treatment.

Authors:  Lifang Hu; Chong Yin; Fan Zhao; Arshad Ali; Jianhua Ma; Airong Qian
Journal:  Int J Mol Sci       Date:  2018-01-25       Impact factor: 5.923

10.  Loss of maternal EED results in postnatal overgrowth.

Authors:  Lexie Prokopuk; Jessica M Stringer; Craig R White; Rolf H A M Vossen; Stefan J White; Ana S A Cohen; William T Gibson; Patrick S Western
Journal:  Clin Epigenetics       Date:  2018-07-13       Impact factor: 6.551

View more
  3 in total

1.  Association between NF-κB Signal Pathway-Related Gene Polymorphisms and Response to Alendronate Treatment in Postmenopausal Chinese Women with Low Bone Mineral Density.

Authors:  Xiaoyi Shen; Sasa Tan; Xianzhen Feng; Wenzhen Fu; Yunqiu Hu; Miao Li; Wenjie Wang; Hu Yuan; Li Liu; Chun Wang; Fei Hua
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-24       Impact factor: 2.629

2.  Methyltransferase Setdb1 Promotes Osteoblast Proliferation by Epigenetically Silencing Macrod2 with the Assistance of Atf7ip.

Authors:  Lijun Zhang; Liqun Xu; Xiaoyan Zhang; Ke Wang; Yingjun Tan; Gaozhi Li; Yixuan Wang; Tong Xue; Quan Sun; Xinsheng Cao; Ge Zhang; Zebing Hu; Shu Zhang; Fei Shi
Journal:  Cells       Date:  2022-08-19       Impact factor: 7.666

3.  Exploration of the Molecular Mechanism of Polygonati Rhizoma in the Treatment of Osteoporosis Based on Network Pharmacology and Molecular Docking.

Authors:  Jinlong Zhao; Fangzheng Lin; Guihong Liang; Yanhong Han; Nanjun Xu; Jianke Pan; Minghui Luo; Weiyi Yang; Lingfeng Zeng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-05       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.